Sihuan Pharmaceutical Holding Group Co., Ltd.is pleased to announce that, PLLA gel (product name: Karlian) (2ml/unit), which is independently researched, developed and manufactured by the Group, has formally obtained the medical device manufacturing license approved by the National Medical Products Administration (“NMPA”) in September 2021.
Karlian is a water-soluble gel product independently researched and developed by the Group. It obtained the registration approval from NMPA on 11 August 2021 and a medical device manufacturing license on 16 September 2021. Karlian is in the form of well-distributed white-like liquid suspension and is delivered in a sterile pre-filled syringe, which helps ensure product safety. It can be used as skin barrier on skin surface or wound, and accelerate the reproducing of collagen and tissue cells on wound.
Poly-L-lactic acid (PLLA) belongs to the family of α-hydroxy acids, serving as the biodegradable material with good biological absorptivity and compatibility. It can be naturally metabolized by the human body, with barely any adverse reaction, and L-lactic acid can also advance metabolism of local skin, improving the quality of skin.
The approval and launch of the first independently researched and developed medical aesthetic product by the Group will further supplement the Group’s product pipelines in the field of medical aesthetic, furthering the forging of the Group’s medical aesthetic product matrix. This would help the Group accelerate the expansion of the self-developed pipelines of medical aesthetic products, improve the comprehensive strengths of the Group and significantly enhance the core competitiveness of the Group in the field of medical aesthetic.